Neuropace
NPCE
24 hedge funds and large institutions have $82M invested in Neuropace in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 3 closing their positions.
217% more capital invested
Capital invested by funds: $25.9M → $82M (+$56.1M)
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
0.69% more ownership
Funds ownership: 69.71% → 70.4% (+0.69%)
0% more funds holding
Funds holding: 24 → 24 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KLC
Kent Lake Capital
Reno,
Nevada
|
+$489K |
| 2 |
Morgan Stanley
New York
|
+$266K |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$229K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$165K |
| 5 |
Millennium Management
New York
|
+$152K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
-$108K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$35.3K |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$29.3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$18.9K |
| 5 |
BlackRock
New York
|
-$7.95K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Jacobs Levy Equity Management
Florham Park,
New Jersey
| – | -$35.3K | -23,692 | Closed |
|
NPCE Hedge Fund Activity: Q1 2023 in Review
24 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Neuropace (NPCE) for Q1 2023, worth a combined $82M — up 217% from $25.9M a quarter earlier.
Fund positioning in NPCE was balanced in Q1 2023: 3 funds opened new positions, 3 closed out, 9 added to existing stakes and 3 trimmed.
The largest buyer was Kent Lake Capital, opening a new position worth an estimated $489K. The largest seller was American Century Companies, exiting entirely with an estimated $108K sold.
- 24 institutional investors held Neuropace (NPCE) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $82M of Neuropace stock for Q1 2023, up 217% quarter-over-quarter.
- 3 funds opened new Neuropace positions in Q1 2023 and 3 closed out, a net change of 0 holders.
- The largest Neuropace buyer in Q1 2023 was Kent Lake Capital, an estimated $489K added.
- The largest Neuropace seller in Q1 2023 was American Century Companies, an estimated $108K sold.
Based on aggregated 13F filings for Q1 2023.